Pillar Biosciences
Natick, US · Delaware corporation · 3 known investors
Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics. Its oncoReveal portfolio of RUO and IVD oncology panels covers solid tumors, hematologic cancers, and liquid biopsy, aiming to deliver faster, lower-cost genomic testing for precision medicine.
Founders & leadership
SL
Shawn LiuNamed on SEC filing
HY
Hui YangNamed on SEC filing
GS
Gang SongNamed on SEC filing
ZW
Zhaohui WangNamed on SEC filing
RF
Robert ForresterNamed on SEC filing
HF
Hong Fang SongNamed on SEC filing
EL
Eric LaiNamed on SEC filing
Board
HF
Hong Fang SangBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$38M disclosed across 2 rounds · 2020–2021
▶$20MraisedJun 2021 · 1 investors · OtherRule 506(b)
▶$20MraisedJun 2021 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Shawn LiuDirector
- Hui YangDirector
- Gang SongExecutive Officer, Director
- Zhaohui WangDirector
- Robert ForresterDirector
- Hong Fang SongDirector
- Eric LaiDirector
- Offering amount
- $50.6M
- Amount sold
- $20M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18MraisedMar 2020 · 10 investors · BiotechnologyRule 506(b)
▶$18MraisedMar 2020 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hong Fang SangDirector
- Shawn LiuDirector
- Hui YangDirector
- Gang SongExecutive Officer, Director
- Zhaohui WangDirector
- Offering amount
- $32.4M
- Amount sold
- $18M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
IQVIA58 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Precision BioSciences56 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Fortis Life Sciences46 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Companies competing with Pillar Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Pillar Biosciences do?
- Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics. Its oncoReveal portfolio of RUO and IVD oncology panels covers solid tumors, hematologic cancers, and liquid biopsy, aiming to deliver faster, lower-cost genomic testing for precision medicine.
- Who are Pillar Biosciences's investors?
- Pillar Biosciences's investors include Catalio Capital Management, LP, HB Ventures, Soleus Capital.
- How much funding has Pillar Biosciences raised?
- Pillar Biosciences has disclosed $38M raised across 2 rounds.
- Where is Pillar Biosciences headquartered?
- Pillar Biosciences is headquartered in Natick, US.